Get the Popular Science daily newsletter💡 Breakthroughs, discoveries, and DIY tips sent six days a week. Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain implant intended to target treatment-resistant depression. The brain-computer interface (BCI) developed by Houston-based startup Motif Neurotech aims to deliver electrical stimulation to activate parts of the brain’s central executive network that are inactive in people with major depressive disorder. If successful, it would make this the first example of a BCI used to treat clinical depression. “The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” Motif CEO and co-founder Jacob Robinson, said in an e-mailed statement. The Motif implant, known as DOT, sits in the bone over the brain region well-established as a target for depression treatment. The DOT, approximately the size of a blueberry, is wirelessly powered and designed to be implanted in a 20-minute outpatient procedure. Image: Motif Neurotech via Businesswire. Treating depression with wireless stimulation …